UNSPSC 51314314: Ascorbic acid/chlorpheniramine/phenylpropanolamine/pyrilamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314314 Ascorbic acid/chlorpheniramine/phenylpropanolamine/pyrilamine is a Commodity code, but the recent state and local procurement activity tagged under it shows minimal alignment with the code's nominal scope. The three recent solicitations on file—a Seminole County, Florida naloxone and drug deactivation systems procurement, a Texas Health and Human Services Commission RFI on direct-to-manufacturer prescription programs, and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products—do not center on the specific antihistamine and decongestant combination the code names. Rather, state and local buyers appear to be using this code as a catch-all for pharmaceutical procurement broadly, including naloxone (an opioid antagonist), generic pharmaceuticals across multiple therapeutic classes, and OTC products. The issuing bodies include county public health departments, state health agencies, and cooperative purchasing vehicles serving multiple state and local jurisdictions. The code shows limited relevant recent activity for vendors focused on the specific ascorbic acid/chlorpheniramine combination or similar formulations.

Geographic activity centers on Florida, Texas, and Minnesota, with MMCAP's reach extending to participating states including Oregon. The Seminole County IFB (Solicitation IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually on a fixed-fee basis with quarterly deliveries and potential FEMA funding. The Texas HHS Commission's RFI (HHS0017013, posted April 3, 2026) explored vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager channels, designed to inform a future formal RFP. MMCAP's RFP (S1070000015802, due March 26, 2026) for generic pharmaceuticals and OTC products requires vendors to provide National Drug Code details, maintain relationships with three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), and certify cGMP and Drug Supply Chain Security Act compliance. Vendors responding to MMCAP must carry commercial general liability of $5,000,000 per occurrence and agree to a 3 percent administrative fee. The code's misalignment with actual procurement scope suggests limited opportunity for vendors specializing in the specific formulation named.